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Chemosensory impairments have been established as a specific indicator of COVID‑19. They affect 
most patients and may persist long past the resolution of respiratory symptoms, representing 
an unprecedented medical challenge. Since the SARS‑CoV‑2 pandemic started, we now know 
much more about smell, taste, and chemesthesis loss associated with COVID‑19. However, the 
temporal dynamics and characteristics of recovery are still unknown. Here, capitalizing on data 
from the Global Consortium for Chemosensory Research (GCCR) crowdsourced survey, we assessed 
chemosensory abilities after the resolution of respiratory symptoms in participants diagnosed with 
COVID‑19 during the first wave of the pandemic in Italy. This analysis led to the identification of two 
patterns of chemosensory recovery, partial and substantial, which were found to be associated with 
differential age, degrees of chemosensory loss, and regional patterns. Uncovering the self‑reported 
phenomenology of recovery from smell, taste, and chemesthetic disorders is the first, yet essential 
step, to provide healthcare professionals with the tools to take purposeful and targeted action to 
address chemosensory disorders and their severe discomfort.
According to the World Health Organization, COVID-19 has been confirmed in more than 113 million cases 
across 223 countries, leading to more than 4.1 million deaths (https:// www. who. int/ emerg encies/ disea ses/ novel- 
coron avirus- 2019, Last update: July 20, 2021). Recent estimates indicate that up to 98% of individuals diagnosed 
with COVID-19 developed forms of chemosensory disorders, most prominently smell  loss1–8. Data collected 
before the COVID-19 pandemic showed that up to 49% of the population report an episode of olfactory loss over 
their lifetime, with 5% of them reporting complete smell loss (anosmia)9–11. Population-based epidemiological 
studies before COVID-19 provide prevalence estimates of smell loss ranging from 2.7 to 24.5%12–16 and taste dis-
orders ranging from 0.6 to 20%14,16. Moreover, in older adults the prevalence of olfactory impairment  increases11.
Reports to date reveal that the COVID-19 pandemic has already significantly increased the prevalence of 
chemosensory disorders worldwide, especially among younger  cohorts1,17, yet the global estimates on chem-
osensory disorders may be markedly underestimated.
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Chemosensory disorders are both early and specific symptoms of COVID-1918–20. Previous studies indicated 
that the timeframe for a full or partial recovery (in particular of the sense of smell) seems to be highly variable, 
spanning from 8 days to even 8  weeks8,21–28. For the vast majority of patients (up to 85%), chemosensory issues 
resolve along with Covid-Like-Illness (CLI) symptoms, in approximately 3  weeks22,27–29. Nevertheless, approxi-
mately from 7 to 37% of patients continue to report chemosensory loss as their main neurological sequelae, which 
persists after the resolution of CLI  symptoms8,22. Therefore, if patients affected by COVID-19 are initially very 
concerned about the development of the infection and the severity of the illness, in a later stage, they develop 
serious concerns for a prompt resolution of smell and taste loss. Persistent smell and taste loss are unexpected 
and invisible disorders associated with a significant reduction in a person’s quality of  life30–32, including increased 
depressive  symptoms30,  anxiety33, sexual  desire34,  nutritional35–38, and safety  issues30,39. It is important to note 
that these side effects are not COVID-specific but characterize patients’ experience affected by smell and taste 
loss because of a variety of  etiologies30,39. During the COVID-19 pandemic, smell and taste loss took center stage, 
exposing the reduced awareness of the national healthcare systems worldwide which were not well prepared to 
address the needs of patients who suffer from smell loss long-term.
Italy has been the first European country to be massively hit by COVID-1940,41 (http:// www. salute. gov. it/ 
imgs/C_ 17_ notiz ie_ 4403_0_ file. pdf), the Lombardy region was particularly affected, reaching the highest 
death toll of the first wave (28 K on 25 February, 2021; https:// www. stati sta. com/ stati stics/ 10993 89/ coron avi-
rus- deaths- by- region- in- italy/)42. As a result, throughout the national territory, and in particular in the most 
affected regions, the need to address COVID-19 long-haulers with chemosensory symptomatology has emerged 
early and  prominently43–46. The Italian National Healthcare system currently lacks capillary specialized assistance 
for patients with smell and taste loss. Approximately 5500 otolaryngologists operate in the country, of which 
only a minority is specialized (approximately 5% of them) in taste and smell disorders (interview with Carmelo 
Zappone, president of Associazione Italiana ORL Libero Professionisti, https:// www. aiolp. it/). Taste and smell 
specialists are mostly located in clinics and centers within hospitals, yet the emergency measures undertaken in 
response to the COVID-19 pandemic have drastically reduced ENT outpatient  activities47,48.
Therefore, to face the exponential increase of patients with taste and smell disorders, a greater number of 
healthcare professionals, including general practitioners as well as frontline healthcare workers, would need 
tools (both objective and subjective tests) to recognize and validate the individual chemosensory experience of 
patients to refer them to specialists. Although psychophysical tests (i.e., Sniffin’Sticks, UPSIT, Taste Strips) are 
important clinical tools to address chemosensory disorders, here we propose that studying the phenomenol-
ogy of recovery from chemosensory loss using patients’ self-reports is the first, yet essential step, to shape a 
purposeful and targeted action to address chemosensory loss and its significant discomfort in patient’s lives. 
Specifically, we tested our pre-registered hypotheses on the self-reports of the Italian participants collected via 
the crowdsourced GCCR  survey49 detailing the phenomenology of self-reported chemosensory abilities before, 
during, and after COVID-19 diagnosis. First, we aimed to describe the patterns of recovery of smell, taste, and 
chemesthetic abilities, individually and in combination, in relation to the timeline of other CLI symptoms. We 
set out to confirm that the chemosensory recovery would be more advanced the farthest from CLI symptom 
onset and for limited losses during the disease; we explored the pattern of recovery based on the different pro-
files of chemosensory loss during the disease. Second, we assessed whether specific demographic information, 
COVID-19 symptoms and/or prior medical conditions constitute risk factors for lengthy or no recovery from 
chemosensory loss within 6 months.
Partial or substantial chemosensory recovery from COVID‑19. Data from a final sample of the 974 
Italian residents who participated in the GCCR online survey between 10th of April 2020 and 17th of Octo-
ber 2020 and who reported partial or full recovery from CLI was used to determine profiles of chemosensory 
recovery patterns. With the goal of limiting the number of questions that a healthcare professional should ask 
to determine the state of chemosensory recovery, we focused on rating scales, which proved to be the most 
accessible way to identify chemosensory loss in individuals positive for COVID-1918. We, therefore, selected 
the ratings on 0–100 scales given to smell (i.e., the ability to perceive the smell of flowers, soap, or garbage but 
not the flavor of food in the mouth), taste (i.e., the ability to perceive sweetness, sourness, saltiness, bitterness 
in the mouth), and chemesthesis abilities (i.e., the ability to perceive the spiciness of chili peppers, the cool-
ing of menthol and the carbonation in soda) after the disease minus their ratings during the disease. Ratings 
significantly differed among before, during, and after the disease for smell [F(2, 2919) = 2451, p < 0.001], taste 
[F(2, 2919) = 1989, p < 0.001], and chemesthesis [F(2, 2919) = 793.5, p < 0.001]. Indeed, participants reported to 
have significantly lost their sense of smell (mean = 11.90, SD = 23.47, Fig. 1A), taste (mean = 20.39, SD = 28.07, 
Fig. 1B) and chemesthesis (mean = 40.81, SD = 32.97, Fig. 1C) during COVID-19 as compared to before COVID-
19 started [smell: mean = 91.14, SD = 16.82, p < 0.001; taste: mean = 92.74, SD = 13.71, p < 0.001; chemesthesis: 
mean = 87.63, SD = 17.30, p < 0.001]. After the resolution of CLI symptoms, on average smell (mean = 53.05, 
SD = 32.22, p < 0.001, Fig.  1A); taste (mean = 60.75, SD = 30.89, p < 0.001, Fig.  1B), and chemesthesis abilities 
(mean = 69.52, SD = 25.80, p < 0.001, Fig. 1C) improved. However, such post-CLI improvement is not homoge-
nous. An exploratory cluster analysis (k-means, bootstrapped stability = 0.98) revealed two chemosensory recov-
ery groups: partial (N = 471, 48.36% of the sample; centroids: smell = 13.4, taste = 10.07, chemesthesis = 7.55) and 
substantial (N = 503, 51.64% of the sample; centroids: smell = 67.2, taste = 68.1, chemesthesis = 48.5; Fig. 2A, B). 
The three chemosensory modalities contributed equally to Dimension 1 that explained 73.2% of the variance 
while chemesthesis recovery was the major contributor to Dimension 2 (Fig. 2B).
Among other characteristics (Table 1), participants who only partially recovered their chemosensory abili-
ties at the time of survey completion were older (mean = 43.16, SD = 11.74) and reported to have contracted 
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the disease earlier (mean = 43.15 days, SD = 23.87) than those who substantially recovered [age: mean = 39.63, 
SD = 10.75, t(972) = 4.89, p < 0.001; days from COVID-19 symptom onset: mean = 40.17, SD = 15.41, t(972) = 2.33, 
p = 0.02].
Paths from chemosensory loss to recovery. To understand whether partial or substantial recovery 
from chemosensory loss is dependent on the specific chemosensory loss experienced during COVID-19, we 
investigated the relationships between clusters of chemosensory loss and recovery (Fig. 3; see also Table 1s in the 
supplemental material for frequencies of single categories). The best clustering profile for chemosensory loss in 
this dataset resulted to be 3 (bootstrapped stability = 0.93): Cluster 1) moderate smell/taste loss and preserved 
chemesthesis (N = 132; centroids: smell = − 20.21, taste = − 19.80, chemesthesis = − 10.71) ; Cluster 2) substantial 
smell, taste, and chemesthesis loss (N = 516; centroids: smell = −  89.4, taste = −  90.16, chemesthesis = -76.61); 
Figure 1.  Loss (during—before ratings; violet) and recovery (after—during ratings; yellow) of smell (A), taste 
(B), and chemesthesis (C). Violin plots represent the smoothed distribution of data; white diamonds indicate the 
mean; whiskers indicate maximum and minimum values.
Figure 2.  (A) Clusters of participants on chemosensory recovery identified by k-means clustering. The 
scatterplot shows each participant’s loading on Dimension 1 (Dim1) and Dimension 2 (Dim2) of the Principal 
Component Analysis. Partial = smell, taste, and chemesthesis partial recovery; Substantial = smell, taste, and 
chemesthesis substantial recovery. (B) Correlations between the three principal components with respect to 
recovery in smell, taste, and chemesthesis. Gray color indicates a positive correlation, whereas shades of red 
indicate negative correlations. Darker shades indicate stronger correlations.
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Cluster 3) substantial smell and taste loss, but preserved chemesthesis (N = 326; centroids: smell = −  87.03, 
taste = − 65.41, chemesthesis = − 14.27).
The majority of individuals with moderate smell/taste loss and preserved chemesthesis (χ2 (2) = 26.92, 
p < 0.001; post-hoc p < 0.001) reported a partial recovery (88.6%, N = 117), and only the 11.4% (N = 15) reported 
substantial recovery. On the contrary, most of the individuals with substantial loss of smell, taste, and chemes-
thesis showed the highest rate of recovery (65.9%, N = 340; partial recovery: 34.1%, N = 176; post-hoc p < 0.001). 
Among the individuals who reported substantial smell and taste loss, but preserved chemesthesis there was no 
significant difference in the reported recovery (substantial recovery: 45.4%, N = 148; partial recovery: 54.6%, 
N = 178; post-hoc p = 0.38; see Fig. 3). Noteworthy, the clusters “moderate smell/taste loss and preserved chemes-
thesis” and “substantial smell and taste loss, but preserved chemesthesis” together account for the 62% of the 
partial recovery cluster, while only for the 32% of the substantial one (χ2 (2) = 46, p < 0.001).
Table 1.  Characteristics of the total sample and the clusters based on chemosensory recovery. Significant 
differences between the two recovery groups are marked in bold.
Variable Full sample (N = 974)
Partial chemosensory recovery 
(N = 471)
Mean (SD) or N
Substantial chemosensory recovery 
(N = 503)
Mean (SD) or N Statistic
Smell recovery 41.14 (35.69) 13.37 (24.97) 67.16 (21.97) t = − 35.59, p < 0.0001
Taste recovery 40.35 (35.58) 10.74 (21.58) 68.07 (20.62) t = − 42.32, p < 0.0001
Chemesthesis recovery 28.71 (34.87) 7.55 (24.08) 48.52 (31.63) t = − 22.83, p < 0.0001
Region of residency (Lombardy) 653 (67%) 292 (61.9%) 361 (71.8%) χ2 = 2.02, p = 0.15
Gender (female) 675 (69.3%) 329 (48.7%) 346 (51.2%) χ2 = 0.0002, p = 0.98
Age 41.33 (11.37), range = 19–78 43.16 (11.74), range = 19–75 39.63 (10.75), range = 19–78 t = 4.88, p < 0.0001
Onset of symptoms (days) 41.61(20), range = 3–177 43.15 (23.87), range = 3–177 40.17 (15.41), range = 7–152 t = 2.30, p = 0.02
COVID-19 diagnosis
591 self-diagnosed (60.6%), 196 lab 
tested (20.1%), 187 clinical assess-
ment (19.2%)
279 self-diagnosed (59.2%), 107 lab 
tested (22.7%), 85 clinical assessment 
(18.02%)
312 self-diagnosed (62.02%), 89 lab 
tested (17.7%), 102 clinical assess-
ment (20.3%)
χ2 = 0.81, p = 0.66
Smokers (yes) 427 (43.8%) 194 (41.18%) 233 (46.3%) χ2 = 0.35, p = 0.55
Prior medical conditions (% based on 
presence of at least one prior medical 
condition)
311 (31.9%) 155 (32.9%) 156 (31.01%) χ2 = 0.02, p = 0.89
Figure 3.  Alluvial plot showing the pattern of chemosensory loss and recovery clusters in relation to days 
between the date of onset and completion of the questionnaire. On the left 3 clusters of chemosensory loss while 
on the right 2 clusters of chemosensory recovery. The flows between the blocks depict the path from loss to 
recovery. The different colors of flows represent the different time intervals (in days) between the date of onset 
and completion of the questionnaire. The width of the flow represents the fraction of participants experiencing 
the recovery either partial or substantial.
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Most participants (71.45%, N = 696) reported the onset of the symptoms within a 31–60 days time frame 
before the completion of the questionnaire. There was no significant difference in the distribution of the chem-
osensory recovery groups or the chemosensory loss groups on the different time frames of the onset of symptoms 
(recovery groups: χ2 (3) = 3.35, p = 0.34; loss groups: χ2 (6) = 4.87, p = 0.56; see Fig. 3).
Association of chemosensory recovery with demographic and clinical predictors. To account 
for individual differences in baseline chemosensory abilities, and in the use of rating scales, we use as indicators 
of the status of the chemosensory functions, the “recovery” as the difference between ratings of patients’ chem-
osensory abilities after- and during- the respiratory illness (Table 2; see the “Method” section).
The model on smell recovery (Table 2) showed a significant main effect of regions (Lombardy, Other Regions), 
indicating that participants living in Lombardy reported higher levels of smell recovery (mean = 42.90, sd = 35.90) 
compared to participants living in other regions (mean = 37.58, sd = 35.04); a significant main effect of age, with 
younger participants reporting higher smell recovery; a significant main effect of the number of symptoms (as the 
total sum of the reported symptoms experienced with the respiratory illness), indicating higher smell recovery 
when a higher number of symptoms are reported; and a significant main effect of time from onset (number of 
days from the reported date of the symptoms onset of respiratory illness, and the date of survey completion) 
Table 2.  Summary of the linear regressions on smell, taste, and chemesthesis recovery. Significant differences 
are marked in bold.
F value Pr( >|t|)
Smell recovery
(Intercept) 2.308  < 0.001
Region 8.155 0.004
Type of diagnosis 2.056 0.128
Number of symptoms 4.274 0.039
Time from onset 0.159 0.689
Smoking 2.104 0.147
Age 10.505 0.001
Region: time from onset 5.647 0.017
Type of diagnosis: number of symptoms 2.242 0.106
Residual standard error: 32.53 on 962 degrees of freedom
Multiple R-squared: 0.1787, adjusted R-squared: 0.1693
F(11, 962) = 19.03, p-value: < 0.001
Taste recovery
(Intercept) 17.29  < 0.001
Region 20.562  < 0.001
Number of symptoms 3.539 0.060
Time from onset 13.95  < 0.001
Smoking 5.514 0.019
Before rating 10.607  < 0.001
Age 24.247  < 0.001
Region: time from onset 11.783  < 0.001
Residual standard error: 34.47 on 966 degrees of freedom
Multiple R-squared: 0.06, adjusted R-squared: 0.06




Type of diagnosis 1.790 0.167
Number of symptoms 0.007 0.93
Time from onset 7.72 0.005
Smoking 4.82 0.028
Before rating 25.095  < 0.001
Age 4.921 0.026
Type of diagnosis: number of symptoms 2.334 0.097
Residual standard error: 34.07 on 963 degrees of freedom
Multiple R-squared: 0.055, adjusted R-squared: 0.045
F(10, 963) = 5.61, p-value: < 0.001
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indicating lower smell recovery when the time from the onset of the disease is longer (see Fig. 1s of the Supple-
mental material for the visualization of main effects). Lastly, there was a significant interaction between regions 
(Lombardy, Other Regions) and time from onset (Fig. 4A). Post-hoc tests showed that in participants residing in 
Lombardy, when the time from the onset of the disease is longer it is associated to lower smell recovery [t(1) = 
− 3.10, p < 0.001]; such effect is not present in participants from other Italian regions [t(1) = 0.40, p = 0.69].
The model on taste recovery (Table 2) showed a significant main effect of regions (Lombardy, Other Regions), 
indicating that participants living in Lombardy reported higher levels of smell recovery (mean = 43.02, sd = 34.97) 
compared to participants living in other regions (mean = 34.91, sd = 36.24); ; a significant main effect of time 
from onset indicating lower taste recovery when the time from the onset of the disease is longer; a main effect of 
age, indicating that older participants reported less taste recovery and a significant main effect of before rating, 
consistent with higher recovery when participants reported higher taste perception before the disease. Effect of 
Smoking (yes, no) was significant as well, suggesting that smokers reported higher taste recovery (mean = 43.04, 
sd = 34.98) compared to non-smokers (mean = 38.24, sd = 35.93; Fig. 2s in the Supplemental material for visu-
alization of main effects). Moreover, a significant interaction between regions and time from onset (Fig. 4B) was 
observed. Post-hoc analyses showed that a longer time from onset of respiratory symptoms was associated with 
lower taste recovery only in participants from the Lombardy region [t(1) =  − 3.74, p < 0.001]; such effect is not 
present in participants from other Italian regions [t(1) = 1.25, p = 0.21].
Results on chemesthesis recovery (Table 2) indicate a significant main effect of age, with older participants 
reporting a smaller index of recovery than younger participants; a significant main effect of before rating, with 
higher recovery in cases it was reported better chemesthesis perception before the disease; a significant main 
effect of time from onset (number of days from the reported date of the symptoms onset of respiratory illness, 
and the date of survey completion) indicating lower chemesthesis recovery when the time from the onset of the 
disease is longer; and a significant main effect of smoking, with smokers reporting higher level of chemesthesis 
recovery (Fig. 3s in the Supplemental material for visualization of main effects).
Discussion
Since the beginning of the COVID-19 pandemic, an increased number of patients with taste and smell loss has 
been reported, and increased evidence emerged in the literature reporting chemosensory deficits as a salient 
feature of the  disease1. The present study aimed to characterize on a larger scale the persistence and recovery 
process of chemosensory deficits associated with SARS-CoV-2 infection, attempting to delineate the expectations 
of recovery for the patients as well as predict/identify groups of patients in need of additional post-viral care.
Current standardized evaluations of smell and taste for clinical purposes, although best practices, require 
lengthy and maskless, thus unsafe, testing  sessions50,51. Additionally, they are not commonly known among 
first-line healthcare professionals. Therefore, in order to recognize early in the disease and characterize over 
time these extremely common long-term consequences of COVID-19, it is of paramount importance to add 
to the first patients’ assessment a set of well-framed informed questions on smell and taste loss and recovery. A 
direct comparison of the objective and subjective chemosensory assessment showed that subjective methods 
(self-reports) might underestimate chemosensory loss in COVID-19  patients1, nevertheless, self-reports can 
provide a first-aid tool to estimate chemosensory loss among the population. The identification and diagnosis 
of chemosensory impairments are the first, yet important, step to make patients fully aware of the problem and 
its less obvious consequences, but also to design strategies to improve their quality of  life39.
A first indication emerging from our analysis is that asking the patient to rate their smell, taste, and ability 
to perceive chemical irritation (chemesthesis) on a 0–100 visual analog scale (VAS) before, during, and after 
the resolution of the respiratory symptoms is a first and important step to understand the recovery. Impor-
tantly, chemesthesis, primarily mediated by the trigeminal nerves, is not only responsible for the detection 
of chemical irritants but it is also involved in inflammatory responses. Most recent reports suggest that this 
Figure 4.  Representation of significant interaction effects of the regression models. Fitted lines of the time from 
onset and region interaction effects on (A) smell recovery and (B) taste recovery.
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inflammatory response is a possible contributor to the exacerbation of the tissue damage induced by viral SARS-
CoV-2  infection52,53. In patients experiencing chemesthesis loss, inflammatory responses might be reduced or 
impaired, decreasing the probability of further damage to the olfactory epithelium. Interestingly, 62.2% of the 
subjects experiencing partial chemosensory recovery showed no chemesthesis loss (37.8% moderate smell/taste 
loss, and 24.8% substantial smell/taste loss), supporting the hypothesis of a contribution of the inflammatory 
response to long term chemosensory loss. It emerges that the evaluation of chemesthesis function, which has 
been mostly neglected outside of the GCCR  efforts18,49, might provide healthcare professionals not only with an 
indication of the outcome of the chemosensory recovery process, but also inform the design of better strategies 
for early treatment of post-viral symptoms.
As observed  previously21,24–26,28,54,55, a demographic factor that should be considered is age. We performed a 
first exploratory cluster analysis (Fig. 2A) that suggested two different patterns of chemosensory recovery: one is 
characterized by moderate smell, taste, and chemesthesis recovery; and a second one by a substantial smell, taste, 
and chemesthesis recovery. These two clusters significantly differ for age of the subjects, with the first group on 
average older than the second. Our analysis then confirms the role of age in the recovery from the chemosensory 
deficits, showing that younger participants are associated with a better chemosensory recovery prognosis than 
older ones for all three chemosensory modalities. Although age-related differences in chemosensory abilities are 
well known, in the case of COVID-19 this relationship is less clear and still controversial. Results from several 
 studies24,28,55 did not find any age-related difference, while Moein et al.8, with an analytic approach similar to 
ours, found that older age had a negative impact on smell recovery, which is in agreement with our results on 
this dataset.
Another interesting aspect of our analysis is that smokers report greater recovery rates for taste and chemes-
thesis than non-smokers. This observation is  controversial56,57, as recent data suggest, smokers risk a more severe 
course of the  disease56,58,59. However, we cannot exclude that this effect could be the result of the temporary absti-
nence from smoking during the disease or the overall limited severity of the disease of participants responding 
to a survey online. It has been reported that the effects of smoking on chemosensory function are short-term60. 
While being a smoker could thus be a confounding question to ask, its statistical link with taste and chemesthesis 
recovery could improve the prognosis.
Finally, our analysis of demographic and clinical predictors for recovery of each sensory modality reveals 
that being resident in Lombardy was predictive of greater smell recovery. Indeed, Lombardy was the epicenter 
of the first wave of the COVID-19 pandemic in Italy, with an overall earlier date of onset and the registering of 
the highest number of cases (and survey participants) in comparison to the rest of Italy. Differences that emerged 
between Lombardy and other regions could be due to differences in the regional management of the pandemic, 
but also to the delayed spreading of the disease in the other regions which registered a relatively low number and 
later onset cases in comparison to Lombardy in the time frame we  analyzed49,58. Alternatively, the differences in 
chemosensory loss among Lombardy and the other regions could be due to the diffusion of the SARS-CoV-2 
D614G haplotype, a variant that by March 1st was predominant in Lombardy and may be responsible for the 
higher rate of chemosensory impairments compared to other  regions61,62.
In Lombardy, the time of onset of the disease is predictive of a worst prognosis of chemosensory recovery, 
confirming the presence of a group of patients whose recovery from any of the symptoms does not occur within 
4–6 weeks from their  onsets63. This result could be related to the high incidence that Lombardy experienced 
during the first  wave42,64, however, this group deserves further investigation, given that the sequela from non-
COVID-19 post-viral chemosensory loss can last on average 1  year65. While regional differences that emerged 
from our analysis could not be used as a first-aid tool to understand the recovery directly by local healthcare 
professionals, they could help in understanding the epidemiological scenario of the pandemic.
Strengths and limitations
To account for individual differences in baseline chemosensory abilities, and in the use of rating scales, we sug-
gest using, as indicators of the status of the chemosensory functions, the "recovery" as the difference between 
ratings of patients’ chemosensory abilities after- and during- the respiratory illness and the "loss’’ as the difference 
between ratings of their chemosensory abilities during- and before-the respiratory illness. One caveat could be 
that of the recovery index suffering from ceiling/floor effect whereby smaller loss might have smaller index of 
recovery. This problem could be solved by comparing the index with a single reference (i.e., comparing to the 
rating before the disease).
Although it has been shown that subjective ratings are a good proxy for the understanding of chemosensory 
loss during the COVID-19  pandemic43,49 (and summarized  by66), in relation to complete and sudden smell loss, 
these measurements are known to have limitations since they might suffer from under- and over-reporting 
 biases8,26,67–69 and possible arbitrary scale usage. Participants who experienced a more severe chemosensory loss 
might tend to overestimate their  recovery67.
Nevertheless, the results of our study are comparable to those obtained with objective testing methods, which 
also observed a similar dependency between loss and recovery, strengthening the evidence that a greater olfac-
tory improvement post-infection is more likely in patients experiencing sudden anosmia or ageusia during the 
viral infection than in those experiencing hyposmia and  hypogeusia23,25.
Despite the afore-mentioned  limitations18,49, the analysis of self-reports of patients’ chemosensory abilities 
is to date the most effective strategy to target the largest number of patients that could not be otherwise reached 
due to the safety policies implemented during the COVID-19 pandemic, as well as the lack of widespread rou-
tine chemosensory testing and the lack of healthcare providers able to rigorously (and reliably) perform  them70.
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Conclusions
With the SARS-CoV-2 pandemic, the number of patients affected by chemosensory loss substantially increased. 
Our work provides indications on the recovery process on which we shaped a scientific-based approach for 
healthcare professionals to characterize the clinical picture of patients reporting chemosensory loss due to 
COVID-19 infection. We further provide indexes such as loss and recovery that would be extremely useful 
for single ENT doctors to have a starting point for further diagnosis and prognosis. Three different profiles of 
chemosensory loss were identified: substantial loss of all the three chemosensory modalities, substantial loss of 
only smell and taste, and moderate loss of only smell and taste. Clinicians must take into account demographic 
factors that influence chemosensory recovery, among them the age as we showed that older adults had a longer 
recovery period. Uncovering the self-reported phenomenology of recovery from smell, taste, and chemesthetic 
disorders is the first, yet essential step, to provide healthcare professionals with the tools to take purposeful and 
targeted action to address chemosensory disorders and its severe discomfort.
Method
The GCCR online survey. The data utilized in this study is part of the GCCR  survey49, which was devel-
oped as a global, crowdsourced online study, and deployed in 35 languages. The survey aimed to measure self-
reported smell, taste, and chemesthesis function, and nasal blockage, amongst other variables, in participants 
with recent (within the past 2  weeks) or current respiratory illness, including COVID-19. Participants were 
asked to rate their ability to smell, taste, and perceive cooling, tingling, and burning sensations (chemesthesis) 
before, during, and, in case of recovery, after their respiratory illness, using 100-point visual analog scales (VAS). 
The online survey was approved as an exempt study by the Institutional Review Board (IRB) of The Pennsylvania 
State University (STUDY00014904) in accordance with the revised Declaration of Helsinki. Informed consent 
was obtained from all participants.
Participants. The entry criterion for participation in the GCCR survey was a recent or current respiratory 
illness (symptoms present in the past 2 weeks). Accordingly, only participants who answered "Yes" to Ques-
tion 6, "Within the past 2 weeks, have you been diagnosed with or suspect that you have a respiratory illness?" 
were allowed to complete the survey (see Appendix 1 of Parma et al.49 for all survey questions). In the present 
study, were included only participants who reported to be resident in Italy (n = 5564) and a COVID-19 diagno-
sis or symptoms [Question 8 "Have you been diagnosed with COVID-19?", answers "No-I was not diagnosed, 
but I have symptoms" (self-diagnosed group), "Yes-diagnosed based on symptoms only" (Clinical assessment 
group), "Yes-diagnosed with viral swab", "Yes-diagnosed with another lab test", (Lab tested group)] (n = 1647). 
In order to investigate chemosensation after the recovery from COVID-19, we included only participants who 
answered “Yes—partly” or “Yes—fully” to Question 28 “Have you recovered from your recent respiratory Ill-
ness or diagnosis? (For example, you no longer have a cough, fever, or shortness of breath.)” (n = 1335). Other 
exclusion criteria were: incomplete ratings (n = 167), no date of onset of respiratory illness symptoms provided 
(n = 166; Question 7: “What date did you first notice symptoms of your recent respiratory illness?”), inconsistent 
responses in questions on smell changes (n = 22; specifically, selecting changes in smell in Question 10 “Have you 
had any of the following symptoms with your recent respiratory illness or diagnosis?”, reporting a difference in 
Question 13 “Rate your ability to smell before your recent respiratory illness or diagnosis” and/or select at least 
one answer from Question 15 “Have you experienced any of the following changes in smell with your recent res-
piratory illness diagnosis?”), age above 100 (n = 1), reported date of onset of respiratory symptoms after the date 
of participation or before January 2020 (n = 5). The final sample included 974 participants (see Fig. 5).
Indices. To standardize statistical analyses, some measures were combined into indices. We defined the time 
from onset as the number of days from the reported date of symptoms onset of respiratory illness and the date of 
survey completion. We defined the number of symptoms as the total sum of the reported symptoms experienced 
with the respiratory illness (“Have you had any of the following symptoms with your recent respiratory illness 
Figure 5.  Flow diagram presenting the selection of the observations included in the present study.
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or diagnosis?” Question 10) and the prior conditions as the total sum of the reported medical conditions expe-
rienced in the 6 months prior to the onset of the respiratory illness (“Did you have any of the following in the 
6 months prior to your recent respiratory illness or diagnosis?” Question 38). Moreover, indices of loss for smell, 
taste, and chemesthesis was computed by subtracting ratings “before illness” (Question 14 “Rate your ability to 
smell BEFORE your recent respiratory illness or diagnosis”) from ratings “during illness” (Question 13 “Rate 
your ability to smell DURING your recent respiratory illness or diagnosis”). Finally, indices of recovery of each 
sense (Smell, taste, and chemesthesis) were computed by subtracting ratings “during illness” from ratings “after 
illness” (Question 29 “Rate your ability to smell AFTER your recovery”).
Statistical analyses. Data was pre-processed and analyzed using the software  R71. Statistical analyses were 
pre-registered at the Open Science Framework (OSF, https:// osf. io/ vun72/) before the data became available. 
First, repeated-measures ANOVA tests (aov function from the R default stats package) were performed on smell, 
taste, and chemesthesis rating with time of rating (before, during, and after the disease) as an independent 
variable. Post-hoc comparisons were performed with Tukey’s test (TukeyHSD function from the R default stats 
package). Then, to investigate whether chemosensory profiles of recovery exist and if they followed the profiles 
found for chemosensory  loss49, we extended the cluster analysis of Parma et al.49 on the Italian dataset, that only 
partially overlapped with the data previously analyzed (594 Italian  residents49). Cluster analyses were performed 
based on the similarities and differences in indexes of smell, taste, and chemesthesis loss, and recovery using the 
k-means function from the R default stats package. The optimal number of clusters was determined with NbClus-
ter72, which tests 30 methods that vary the combinations of cluster numbers and distance measures for the 
k-means clustering. Cluster stability was estimated through a bootstrapping approach (100 iterations) with the 
bootcluster  package73. Descriptive analyses on the resulting clusters were run using t-tests (stats  package74) and 
chi-square tests (chisq.test function of the stats  package74). Pairwise comparisons after chi-square tests were per-
formed using the chisq.multcomp function of the RVAideMemoire package. Next, smell, taste, and chemesthesis 
recovery were investigated through three separate multiple linear regression models (lm function of stats pack-
age) with the same predictors. Predictors included continuous and categorical variables. The former included: 
age, number of symptoms, time from onset, prior conditions, and the rating of the dependent variable (e.g., 
smell for smell recovery) related to before the disease (“Before rating”); the latter included: region of residence 
(Lombardy, Other regions), type of diagnosis (Self-diagnosed, Clinical assessment, or lab tested), smoking (yes, 
no; also including e-cigarette). In order to explore the recovery profile and region specificity, in the models, we 
included interaction between these variables: region of residence, type of diagnosis, number of symptoms, and 
time from onset. To avoid overly complicated and uninterpretable models, only second-level interactions were 
included. To ensure that each predictor improved the models’ fit, the function step (stats package) was used to 
perform automatic backward elimination, which relies on the AIC  criterion75. Factors that did not significantly 
improve the models’ fit were removed. AIC values of the initial and final models were calculated using the 
ANOVA function (stats  package74). Collinearity was calculated with the Variance Inflation Factors (VIF) using 
the vif function of the car  package76. Interactions including continuous factors were analyzed according to Aiken 
& West’s  method77. RStudio software and package ggplot78 were used to build all the graphs in the manuscript 
and all the scripts along with information on the computational environment and dependencies will be found, 
upon acceptance of the manuscript, at OSF (https:// osf. io/ vun72/).
In the light of recent studies from the GCCR  dataset18,49,79, additions to the pre-registered linear models were 
necessary: (1) smell, taste and chemesthesis ratings were not analyzed as repeated measures (before, during, after) 
but rather index of recovery was computed and used as dependent variable and the before rating was included 
in the model as independent variable to better characterize the degree of changes; (2) since in cluster analyses 
age was significantly different between the two clusters, it was included as fixed and not anymore as a random 
factor; (3) gender and type of recovery were removed because they did not improve the models’ fit. Due to the 
particular spread of the pandemic in Italy, the region of residence was also included as a predictor.
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